Literatur

Zelltherapie mit Granulozyten, Lymphozyten und Natürlichen Killerzellen

(1) *Arnold R, Pflieger H, Dietrich M, Heimpel H. The clinical efficacy of granulocyte transfusions: studies on the oral cavity. Blut. 1977; 35: 405-414.*

(2) *Rutella S, Pierelli L, Sica S et al. Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy. 2003; 5: 19-30.*

(3) *Liles WC, Huang JE, Llewellyn C et al. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion. 1997; 37: 182-187.*

(4) *Heuft HG, Goudeva L, Sel S, Blasczyk R. Equivalent mobilization and collection of granulocytes for transfusion after administration of glycosylated G-CSF (3 microg/kg) plus dexamethasone versus glycosylated G-CSF (12 microg/kg) alone. Transfusion. 2002; 42: 928-934.*

(5) *Lee JH, Leitman SF, Klein HG. A controlled comparison of the efficacy of hetastarch and pentastarch in granulocyte collections by centrifugal leukapheresis. Blood. 1995; 86: 4662-4666.*

(6) *Wissenschaftlicher Beirat der Bundesärztekammer. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). www.baek.de. 2005.*

(7) *Bux J, Einsele H. Granulozytenkonzentrate. In: Bundesärztekammer, ed. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Köln: Deutscher Ärzte-Verlag; 2003: 51-61.*

(8) *Council of Europe. Council of Europe Guide to the Preparation, Use and Quality Assurance of Blood Components. 9th edition. 2005. Strasbourg, France, Council of Europe Publishing.*

(9) *Worel N, Kurz M, Peters C, Hocker P. Serial granulocytapheresisunder daily administration of rHuG-CSF: effects on peripheral blood counts, collection efficiency, and yield. Transfusion. 2001; 41: 390-395.*

(10) *von Laer D, Serr A, Meyer-Konig U et al. Human cytomegalovirus immediate early and late transcripts are expressed in all major leukocyte populations in vivo. J Infect Dis. 1995; 172: 365-370.*

(11) *Nichols WG, Price T, Boeckh M. Donor serostatus and CMV infection and disease among recipients of prophylactic granulocyte transfusions. Blood. 2003; 101: 5091-5092.*

(12) *Vij R, DiPersio JF, Venkatraman P et al. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood. 2003; 101: 2067-2069.*

(13) *Lightfoot T, Gallelli J, Matsuo K et al. Evaluation of solutions for the storage of granulocyte colony-stimulating factor-mobilized granulocyte concentrates. Vox Sang. 2001; 80: 106-111.*

(14) *Schmitt A, Reinhardt P, Schmitt M et al. Functional State of steroid- versus G-CSF-mobilized granulocytes: Considerations about the storage of granulocyte concentrates for neutropenic patients. Infusionsther Transfusionsmed. 2002; 29: 57-64.*

(15) *Lightfoot T, Leitman SF, Stroncek DF. Storage of G-CSF-mobilized granulocyte concentrates. Transfusion. 2000; 40: 1104-1110.*

(16) *McCullough J, Weiblen BJ, Fine D. Effects of storage of granulocytes on their fate in vivo. Transfusion. 1983; 23: 20-24.*

(17) *Lane TA, Lamkin GE. Adherence of fresh and stored granulocytes to endothelial cells. Effect of storage temperature. Transfusion. 1988; 28: 237-242.*

(18) *Bux J, Cassens U, Dielschneider T et al. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang. 2003; 85: 322-325.*

(19) *Wiesneth M, Burkhart J, Meyer T, Schrezenmeier H. Hämatopoietische Stammzelltransplantationen: Gewinnung, Präparation, klinischer Einsatz. Hämotherapie. 2004; 3: 16-34.*

(20) Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med. 1981; 304: 1185-1189.

(21) Dale DC, Liles WC, Summer WR, Nelson S. Review: granulocyte colony-stimulating factor-role and relationships in infectious diseases. J Infect Dis. 1995; 172: 1061-1075.

(22) Jilma B, Hergovich N, Homoncik M et al. Rapid down modulation of P-selectin glycoprotein ligand-1 (PSGL-1, CD162) by G-CSF in humans. Transfusion. 2002; 42: 328-333.

(23) Stroncek DF, Leonard K, Eiber G et al. Alloimmunization after granulocyte transfusions. Transfusion. 1996; 36: 1009-1015.

(24) Price TH, Bowden RA, Boeckh M et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000 Jun 1; 95(11): 3302 -9. 95: 3302-3309.

(25) Cesaro S, Chinello P, De Silvestro G et al. Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases. Support Care Cancer. 2003; 11: 101-106.

(26) Lee JJ, Chung IJ, Park MR et al. Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia. 2001; 15: 203-207.

(27) Stanworth S, Massey E, Hyde C et al. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2005; CD005339.

(28) Mohan P, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. Cochrane Database Syst Rev. 2003; CD003956.

(29) Singer MS, Seibel NL, Vezina G, Choi SS, Dinndorf PA. Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia. J Pediatr Hematol Oncol. 2003; 25: 252-256.

(30) Grigull L, Schrauder A, Schmitt-Thomssen A, Sykora K, Welte K. Efficacy and safety of G-CSF mobilized granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infection. Infection. 2002; 30: 267-271.

(31) Cairo MS, Worcester CC, Rucker RW et al. Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy for neonatal neutropenia and sepsis. J Pediatr. 1992; 120: 281-285.

(32) Hubel K, Carter RA, Liles WC et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion. 2002; 42: 1414-1421.

(33) Kerr JP, Liakopolou E, Brown J et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol. 2003; 123: 114-118.

(34) von Planta M, Ozsahin H, Schroten H, Stauffer UG, Seger RA. Greater omentum flaps and granulocyte transfusions as combined therapy of liver abscess in chronic granulomatous disease. Eur J Pediatr Surg. 1997; 7: 234-236.

(35) Lee JJ, Song HC, Chung IJ et al. Clinical efficacy and prediction of response to granulocyte transfusion therapy for patients with neutropenia-related infections. Haematologica. 2004; 89: 632-633.

(36) Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990; 76: 2462-2465.

(37) Kolb HJ, Schmid C, Weisser M et al. Cytoreduction, DLI, or mobilized peripheral blood progenitors. Ann Hematol. 2002; 81 Suppl 2: S30-S33.

(38) Slavin S, Morecki S, Weiss L, Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res. 2002; 11: 265-276.

(39) Feinstein L, Sandmaier B, Maloney D et al. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann N Y Acad Sci. 2001; 938: 328-337.

(40) Bacigalupo A, Palandri F. Management of acute graft versus host disease (GvHD). Hematol J. 2004; 5: 189-196.

(41) Michallet AS, Nicolini F, Furst S et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant. 2005; 35: 601-608.

(42) Peggs KS, Thomson K, Hart DP et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004; 103: 1548-1556.

(43) Wiesneth M, Schreiner T, Friedrich W et al. Combined CD34 positive plus CD2 negative selection for effective T-cell depletion as GvHD-prophylaxis in HLA-nonidentical blood progenitor cell transplantation. Transfus Sci. 1996; 17: 629-635.

(44) Gilleece MH, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma. 2003; 44: 23-28.

(45) Zeiser R, Bertz H, Spyridonidis A, Houet L, Finke J. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant. 2004; 34: 923-928.

(46) Massenkeil G, Roigas J, Nagy M et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant. 2004; 34: 309-316.

(47) Bishop MR, Fowler DH, Marchigiani D et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004; 22: 3886-3892.

(48) Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005; 23: 5675-5687.

(49) Teichmann JV, Ludwig WD, Thiel E: Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. Leuk Res 1992;16(3):287-98

(50) Pawelec G: MHC-unrestricted immune surveillance of leukemia. Cancer Biother 1994; 9(3): 265-288.

(51) Storkus WJ, Dawson JR: Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. Crit Rev Immunol 1991; 10(5): 393-416.

(52) Smyth MJ, Hayakawa Y, Takeda K, Yagita H: New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2(11): 850-861.

(53) Chumbley G, King A, Robertson K, Holmes N, Loke YW: Resistance of HLA-G and HLA-A2 transfectants to lysis by decidual NK cells. Cell Immunol 1994; 155(2): 312-322

(54) Mandelboim O, Pazmany L, Davis DM, Vales-Gomez M, Reyburn HT, Rybalov B, Strominger JL: Multiple receptors for HLA-G on human natural killer cells. Proc Natl Acad Sci U S A 1997; 94(26): 14666-14670.

(55) Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295(5562): 2097-100.

(56) Uharek L, Zeis M, Glass B, Steinmann J, Dreger P, Gassmann W, Schmitz N, Muller-Ruchholtz W: High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Leukemia 1996; 10: 1758-1764.

(57) Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL, Lotze MT: Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res 2001; 61(3): 884-888.

(58) *Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D: IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004: 33(3): 261-266.*

(59) *Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson JA, Petersen FB, Fefer A: Interleukin-2 with or without lymphokine-activated killer cell as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12(2): 159-163.*

(60) *Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76(5): 840-852.*

(61) *Fujimiya Y, Suzuki Y, Katakura R, Ohno T: Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients. J Hematother 1999; 8(1): 29-37.*

(62) *Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85(8): 622-632.*

(63) *Kimoto Y, Tanaka T, Tanji Y, Fujiwara A, Taguchi T: Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. Biotherapy 1994; 8(1): 41-50*

(64) *Nagayama H, Takahashi S, Takahashi T, Ogami K, Ikebuchi K, To Tani K, Asano S: IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23(2): 183-185*

(65) *Whiteside TL, Vujanovic NL, Herberman RB: Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998; 230: 221-244.*

(66) *Gong JH, Maki G, Klingemann HG: Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8: 652-658*

(67) *Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, O Reilly RJ: Antileukemia activity of a natural killer cell line against human leukemia. Clin Cancer Res 1998; 4: 2859-2868.*

(67) *Drexler HG and Matsuo Y: Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia 2000; 14: 777-782.*

(68) *Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematoth Stem Cell Res 2001; 10(4): 535-544.*

(69) *Uherek C, Groner B, Wels W: Chimeric antigen receptors for the retargeting of cytotoxic effector cells. J Hematother Stem Cell Res 2001; 10: 523-534.*

(70) *Wiesneth M, Hertenstein B, Bunjes D, Schmeiser T, Arnold R, Heimpel H, Heit W. T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia. Eur J Haematol 1988; 41: 243-249.*

Literatur

Die neuen Richtlinien

(-) *Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie); Fassung 2000; Deutscher Ärzte-Verlag*

(-) *Bundesärztekammer: Vorabinformation über die Novellierung 2005 der Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) gemäß §§ 12 u. 18 TFG*

(-) *Mitteilung des Arbeitskreis Blut des Bundesministeriums für Gesundheit und soziale Sicherung: Aktuelle Empfehlungen zur autologen Hämotherapie (Votum 32 vom 17. 3. 2005)*

(-) *Kretschmer V, Karger R : Neue Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) – Änderungen, Interpretationen und Kommentar; Infus Ther Transfus Med 2001; 28: 24 - 43, 82 - 94*

(-) *Nagl D: Die neuen „Richtlinien", in:* **„hämotherapie"** *– Journal für das Krankenhaus (Blutspendedienst des Bayerischen Roten Kreuzes gGmbH), Hefte 1/2001, 2/2001, Sonderausgabe 2002 zum DGTI-Kongress, 1/2003*

Literatur

Anti-HBc–Ein neuer und zugleich alter Marker in der Routinetestung von Blutspendern

(1) *Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie), Fassung 2000, Mit Neufassung und Kommentaren 2001, Deutscher Ärzte-Verlag Köln*

(2) *Bekanntmachung des Arbeitskreises Blut des Bundesministeriums für Gesundheit, Votum (V24), Verfahren zur Rückverfolgung (Look Back) (gemäß § 19 Transfusionsgesetz), Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz 2001, 44: 305-316, Springer Verlag*

(3) *Bekanntmachung des Arbeitskreises Blut des Bundesministeriums für Gesundheit; Votum (V31), Erhöhung der Sicherheit von zellulären Blutkomponenten und quarantänegelagertem Frischplasma durch Untersuchung der Blut und Plasmaspenden auf Antikörper gegen das Hepatitis-B-Core-Antigen (Anti-HBc), Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz 2005, 48: 698-699, Springer Medizin Verlag*

(4) *W. K. Roth et al., NAT for HBV and anti-HBc testing increase blood safety, TRANSFUSION 2002, 42: 869-875.*